Nonanthracycline TC Adjuvant Chemo Superior for Operable Breast Cancer
14th Dec 2005, 03:11 GMT
Results showed significantly superior disease-free survival and favorable overall survival with the adjuvant docetaxel-cyclophosphamide (TC) regimen compared with doxorubicin-cyclophosphamide (AC). Medscape Medical News
Nonanthracycline TC Adjuvant Chemo Superior for Operable Breast Cancer related news:
- New Study Demonstrates Nonanthracycline Adjuvant Regimen TC Is Superior to Standard AC for Early Breast Cancer — Mammography News from StratCenter.com
- Fatigue fairly uncommon after breast cancer chemo (Reuters) —
- Fatigue fairly uncommon after breast cancer chemo — RedOrbit News - Health
- SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast Cancer Adjuvant Therapy — MedPage Today.com Latest Headlines
- Dose-Dense Adjuvant Chemo Regimen Safe, More Effective for Selected Breast Cancer Patients — Medscape Medical News Headlines
- 'I just got breast cancer.' — Breast Cancer Chronicles
- NHS under pressure to provide new breast cancer drugs — News-Medical News Feed
- SABCS: Shorter Chemotherapy Regimen Plus Taxol Reduces Breast Cancer Recurrence — MedPage Today Hematology/Oncology
- Gene variation affects tamoxifen's benefit for breast cancer — EurekAlert! - Cancer
- Aromatase inhibitor shows promise for breast cancer patients — The Cancer Blog
Latest news from Medscape Medical News Headlines:
- Effective Asthma Management Strategies Linked to Better Long-term Asthma Control
- Abatacept for Rheumatoid Arthritis Well Tolerated After 2 Years
- Immunotherapy Possible Option for Women With HPV and Cervical Abnormalities
- Novel Ragweed Vaccine Shown to be Safe, Effective in the Long term for Mild to Severe Allergy